Thailand vs Ukraine: Average cost of drugs for extensively drug-resistant tuberculosis
Thailand
1,561 constant 2022 US$
in 2024
Ukraine
1,566 constant 2022 US$
in 2024
Thailand rank
32nd
Ukraine rank
31st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Thailand
- Ukraine
How they compare
Ukraine currently reports 1,566 constant 2022 US$ against 1,561 constant 2022 US$ in Thailand, a difference of 5 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Thailand ahead.
Thailand ranks 32nd and Ukraine ranks 31st of 56 countries.
Ukraine has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Thailand | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,958 constant 2022 US$ | 5,398 constant 2022 US$ | 1,439 constant 2022 US$ | Ukraine |
| 2020s | 2,431 constant 2022 US$ | 3,686 constant 2022 US$ | 1,255 constant 2022 US$ | Ukraine |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Thailand or Ukraine?
- Ukraine, at 1,566 constant 2022 US$ against 1,561 constant 2022 US$ in Thailand as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Thailand and Ukraine?
- 5 constant 2022 US$, with Ukraine ahead.
- How many years of comparable data are there for Thailand and Ukraine?
- 8 years are reported by both, from 2017 to 2024.
- How do Thailand and Ukraine rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Thailand ranks 32nd and Ukraine ranks 31st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.